title: Lactococcus lactis NCC 2287 alleviates food allergic manifestations in sensitized mice by reducing IL-13 expression specifically in the ileum.
abstract: OBJECTIVE
  Utilizing a food allergy murine model, we have investigated the intrinsic antiallergic potential of the Lactococcus lactis NCC 2287 strain.
  
  
  METHODS
  BALB/c mice were sensitized at weekly intervals with ovalbumin (OVA) plus cholera toxin (CT) by the oral route for 7 weeks. In this model, an oral challenge with a high dose of OVA at the end of the sensitization period leads to clinical symptoms. Lactococcus lactis NCC 2287 was given to mice via the drinking water during sensitization (prevention phase) or after sensitization (management phase).
  
  
  RESULTS
  Lactococcus lactis NCC 2287 administration to sensitized mice strikingly reduced allergic manifestations in the management phase upon challenge, when compared to control mice. No preventive effect was observed with the strain. Lactococcus lactis NCC 2287 significantly decreased relative expression levels of the Th-2 cytokine, IL-13, and associated chemokines CCL11 (eotaxin-1) and CCL17 (TARC) in the ileum. No effect was observed in the jejunum.
  
  
  CONCLUSIONS
  These results taken together designate Lactococcus lactis NCC 2287 as a candidate probiotic strain appropriate in the management of allergic symptoms.
authors.affiliation: Allergy Group, Department of Nutrition and Health, Nestle Research Center, Vers-chez-les-Blanc, 1000 Lausanne 26, Switzerland.
authors.forename: Adrian W
authors.initials: AW
authors.lastname: Zuercher
authors.forename: Marietta
authors.initials: M
authors.lastname: Weiss
authors.forename: Sébastien
authors.initials: S
authors.lastname: Holvoet
authors.forename: Mireille
authors.initials: M
authors.lastname: Moser
authors.forename: Hélène
authors.initials: H
authors.lastname: Moussu
authors.forename: Laurence
authors.initials: L
authors.lastname: van Overtvelt
authors.forename: Stéphane
authors.initials: S
authors.lastname: Horiot
authors.forename: Philippe
authors.initials: P
authors.lastname: Moingeon
authors.forename: Sophie
authors.initials: S
authors.lastname: Nutten
authors.forename: Guénolée
authors.initials: G
authors.lastname: Prioult
authors.forename: Anurag
authors.initials: A
authors.lastname: Singh
authors.forename: Annick
authors.initials: A
authors.lastname: Mercenier
mesh_terms: D000284:Administration, Oral; D000818:Animals; D054413:Chemokine CCL11 / Q000037:antagonists & inhibitors* / Q000096:biosynthesis; D054414:Chemokine CCL17 / Q000037:antagonists & inhibitors* / Q000096:biosynthesis; D002772:Cholera Toxin / Q000008:administration & dosage / Q000009:adverse effects; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D005512:Food Hypersensitivity / Q000276:immunology / Q000378:metabolism / Q000628:therapy; D007082:Ileum / Q000187:drug effects / Q000276:immunology* / Q000378:metabolism; D007073:Immunoglobulin E / Q000032:analysis; D007074:Immunoglobulin G / Q000032:analysis; D018793:Interleukin-13 / Q000037:antagonists & inhibitors* / Q000096:biosynthesis; D013294:Lactococcus lactis / Q000378:metabolism*; D051379:Mice; D008807:Mice, Inbred BALB C; D010047:Ovalbumin / Q000008:administration & dosage / Q000009:adverse effects; D019936:Probiotics / Q000008:administration & dosage* / Q000627:therapeutic use
chemical_list: C499538:Ccl17 protein, mouse; D054413:Chemokine CCL11; D054414:Chemokine CCL17; D007074:Immunoglobulin G; D018793:Interleukin-13; D007073:Immunoglobulin E; D010047:Ovalbumin; D002772:Cholera Toxin